Research programme: lipocalin derivatives - Pieris Pharmaceuticals/Daiichi Sankyo

Drug Profile

Research programme: lipocalin derivatives - Pieris Pharmaceuticals/Daiichi Sankyo

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Pieris
  • Developer Pieris Pharmaceuticals
  • Class Recombinant proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 18 Apr 2013 Preclinical trials in Undefined indication in Germany (unspecified route)
  • 09 Oct 2012 Pieris achieves its first of two milestones in the collaboration with Daiichi
  • 12 Apr 2011 Early research in Undefined indication in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top